Triglyceride–glucose related index and its association with coronary heart disease risk in patients with metabolic dysfunction-associated steatotic liver disease: a retrospective analysis based on type 2 diabetes mellitus - Report - MDSpire
Advertisement
Triglyceride–glucose related index and its association with coronary heart disease risk in patients with metabolic dysfunction-associated steatotic liver disease: a retrospective analysis based on type 2 diabetes mellitus
Clinical Report: Association of the Triglyceride-Glucose Index with CHD Risk
Overview
This study investigates the association between the triglyceride-glucose (TyG) index and coronary heart disease (CHD) risk in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), particularly focusing on those with type 2 diabetes mellitus (T2DM). The findings indicate that TyG is a significant predictor of CHD risk, with a stronger association observed in T2DM patients.
Background
Metabolic dysfunction-associated steatotic liver disease (MASLD) is a prevalent condition linked to insulin resistance and various cardiovascular diseases, including coronary heart disease (CHD). Understanding the relationship between insulin resistance markers, such as the triglyceride-glucose (TyG) index, and CHD risk is crucial for managing patients with MASLD, especially those with coexisting type 2 diabetes mellitus (T2DM). This study aims to clarify the impact of TyG on CHD risk stratified by T2DM status.
Data Highlights
Variable
Odds Ratio (OR)
TyG
2.035
T2DM
2.107
TyG in T2DM
3.34
TyG without T2DM
1.89
TyG cut-off (T2DM)
9.005
TyG cut-off (without T2DM)
7.992
Key Findings
The TyG index is positively correlated with CHD risk (OR = 2.035).
Patients with T2DM have a higher risk of CHD (OR = 2.107).
The association between TyG and CHD is stronger in T2DM patients (OR = 3.34).
Several biochemical indices, including LDL and HbA1c, are associated with increased CHD risk.
HDL and eGFR are identified as protective factors against CHD.
ROC analysis indicates specific cut-off values for TyG that significantly increase CHD risk.
Clinical Implications
The TyG index can serve as a practical tool for assessing CHD risk in patients with MASLD, particularly in those with T2DM. Clinicians should consider integrating TyG measurements into routine evaluations to enhance risk stratification and management strategies for cardiovascular health in this population.
Conclusion
The study underscores the importance of the TyG index as a significant predictor of CHD risk in patients with MASLD, with a pronounced effect in those with T2DM. These findings highlight the need for targeted cardiovascular risk management in this high-risk group.
The use of wearable devices for health monitoring has attracted significant interest from patients, physicians, and other healthcare professionals because of their potential to usher in a new era of personalized, accessible, and convenient care. This article explores the use of wearable technology for monitoring retinal health, both through direct assessment of ocular parameters—such as visual field testing and imaging—and through systemic monitoring of surrogate markers of retinal health.
